Medicine
Bucapsol 7.5 mg capsule
Bucapsol 7.5 mg capsule is a prescription medicine containing Buspirone for oral use, marketed by Pangea Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59°…
Key facts
- Active ingredient (INN)
- Buspirone
- Brand
- Bucapsol
- Strength
- 7.5 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 30 capsules, 60 capsules
- Marketing authorisation holder
- Pangea Pharmaceuticals
- Manufacturer
- Pangea Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N05BE01 Buspirone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 April 2026
- Identifiers
- RxCUI 2708991, 2708993, 2708994 +5DailyMed set ID f101c5f3-d533-474d-a8bf-90d054933d16NDC 81279-122Application ANDA218628
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 capsule in 1 bottle | 81279-122-30 | Pangea Pharmaceuticals | 10 April 2026 |
| 60 capsule in 1 bottle | 81279-122-60 | Pangea Pharmaceuticals | 10 April 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 September 1986 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Buspirone 7.5 mg capsule.
Other strengths and forms of Buspirone
Clinical summary
Buspirone is a prescription medicine indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. It is available as tablets and capsules for oral use. MedsAcross supplies Buspirone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BuspironeFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Buspirone Hydrochloride prescribing information (Accord Healthcare) · U.S. National Library of Medicine, DailyMed
Need Bucapsol 7.5 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.